SDTM, ADaM, and SEND datasets form the backbone of regulatory submissions to the FDA, PMDA, and other agencies. Yet validation failures in these datasets remain one of the most common obstacles to achieving submission readiness. Understanding why these failures occur helps clinical data managers and operations leaders address root causes rather than just fixing...
Why Selecting the Right SEND Dataset Service Matters FDA-compliant SEND dataset services determine whether your nonclinical submission clears the gateway or gets rejected. With SENDIG v3.1.1 now required for studies starting after March 15, 2023, and SENDIG-Genetox v1.0 mandated for studies beginning after March 15, 2025, biopharma R&D leaders and clinical data managers face a...
Clinical data automation platforms have become essential for large biopharma R&D teams working to bridge the gap between preclinical findings and clinical outcomes. When your organization invests significant resources in discovery and nonclinical studies, that data needs to flow into clinical programs without friction or loss of context. PointCross Life Sciences helps organizations connect...
Most nonclinical CROs take 8 to 10 weeks to deliver a study report and its SEND dataset, because two teams rebuild the same data twice. Here's how producing both from one governed source cuts that to 2 to 3 weeks after data lock, without loosening a single FDA requirement.
SEND datasets are the standardized, machine-readable files the U.S. FDA requires for nonclinical study data in most drug and biologics submissions. If you run toxicology studies, assemble regulatory filings, or manage data at a CRO, SEND datasets are no longer optional for in-scope studies. This guide explains what SEND is, who needs it, which...
CDISC opened public review for SENDIG v4.0 in April 2026, with publication targeted for Q4 2026. While the FDA has not yet announced an implementation timeline, many CROs and sponsors are watching from a distance. That posture has a cost. SENDIG v4.0 isn't just another version update. It introduces some of the most significant structural changes since its original release. The changes extend far beyond routine version...
This article breaks down the real SEND compliance challenges that nonclinical CROs face, grounded in current FDA and CDISC requirements, and shows where disciplined process and the right tooling change the outcome. We write this for toxicologists, regulatory affairs professionals, bioinformaticians, pharma and biotech executives, and the IT and data teams who live with...
The study report and its SEND dataset are built twice from the same data. Automating nonclinical study reports deletes that duplication, cuts cost 30 to 50 percent, and removes the inconsistencies that trigger FDA queries.
Complete FDA SEND guide: which nonclinical studies require SEND datasets, SENDIG 3.1.1, DART, AR, Genetox deadlines, GLP rules, and IND/NDA scope explained.
Discover how AI is transforming nonclinical study reporting, from automated Module 2.4 drafts to FDA-compliant eCTD outputs. What is working, what is not, and what the FDA's 2025 guidance requires.